Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 May:58:27-36.
doi: 10.1016/j.ijid.2017.02.016. Epub 2017 Mar 9.

Dengue virus serological prevalence and seroconversion rates in children and adults in Medellin, Colombia: implications for vaccine introduction

Affiliations

Dengue virus serological prevalence and seroconversion rates in children and adults in Medellin, Colombia: implications for vaccine introduction

Mabel Carabali et al. Int J Infect Dis. 2017 May.

Abstract

Background: Dengue is an important public health problem worldwide. A vaccine has recently been licensed in some countries of Latin America and Asia. Recommendations for dengue vaccine introduction include endemicity and a high serological prevalence of dengue in the territories considering its introduction.

Methods: A community-based survey was conducted to estimate dengue seroprevalence and age-specific seroconversion rates in a community in Medellin, Colombia, using a dengue serological test (IgG indirect ELISA). Residents were selected at random and were first screened for dengue infection; they were then followed over 2.5 years.

Results: A total of 3684 individuals aged between 1 and 65 years participated in at least one survey. The overall dengue seroprevalence was 61%, and only 3.3% of seropositive subjects self-reported a past history of dengue. Among dengue virus (DENV)-naïve subjects with more than two visits (n=1002), the overall seroconversion rate was 8.7% (95% confidence interval 7.3-10.4) per 1000 person-months, over the study period. Overall, the mean age of DENV prevalent subjects was significantly higher than the mean age of seroconverted subjects. Specifically, DENV seropositivity over 70% was observed in participants over 21 years old. Serotype-specific plaque-reduction neutralization tests (PRNT) revealed that all four dengue serotypes were circulating, with DENV4 being most prevalent.

Conclusions: These laboratory-based findings could inform dengue vaccine decisions, as they provide age-specific seroprevalence and seroconversion data, evidencing permanent and ongoing dengue transmission in the study area. This study provides evidence for the existing rates of secondary and heterotypic responses, presenting a challenge that must be addressed adequately by the new vaccine candidates.

Keywords: Colombia; Dengue; Dengue burden; Dengue prevalence; Dengue seroconversion; Serological survey.

PubMed Disclaimer

Figures

None
Graphical abstract
Figure 1
Figure 1
Flow chart of enrollment and participation.
Figure 2
Figure 2
Overall dengue virus (DENV) seroprevalence by neighborhood. Map of Santa Cruz sub-district, indicating the proportion of DENV serological prevalence by IgG indirect ELISA in each neighborhood.
Figure 3
Figure 3
Seroconversion rate per visit. Overall seroconversion rate in dengue-naïve subjects at baseline by follow-up time. Includes the number at risk at the beginning of the time period and the number of events (new infections) in parenthesis. The curve shows an increasing probability of seroconversion over time.
Figure 4
Figure 4
Distribution of seroconversion by neighborhood (rate). Map of Santa Cruz sub-district indicating the proportion of dengue virus seroconversion (negative to positive antibodies) by IgG Indirect ELISA in each of the 11 neighborhoods.
Figure 5
Figure 5
Overall probability of dengue seroconversion by age group. Seroconversion probabilities adjusted by sex, neighborhood, visits, presence of fever, and all other covariates in the model (n = 1002).

Similar articles

Cited by

References

    1. World Health Organization . WHO; Geneva: 2012. Global strategy for dengue prevention and control 2012–2020. WHO/HTM/NTD/VEM/2012.5. August.
    1. Messina J.P., Brady O.J., Scott T.W., Zou C., Pigott D.M., Duda K.A. Global spread of dengue virus types: mapping the 70 year history. Trends Microbiol. 2014;22:138–146. - PMC - PubMed
    1. Bhatt S., Gething P.W., Brady O.J., Messina J.P., Farlow A.W., Moyes C.L. The global distribution and burden of dengue. Nature. 2013;496:504–507. - PMC - PubMed
    1. Tuiskunen Bäck A., Lundkvist Å. Dengue viruses—an overview. Infect Ecol Epidemiol. 2013;3:18839. - PMC - PubMed
    1. Vos T., Allen C., Arora M., Barber R.M., Bhutta Z.A., Brown A. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1545–1602. - PMC - PubMed

MeSH terms